Oral composition comprising 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionic acid or salt thereof
An oral composition contains 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or a salt thereof and polyvinylpyrrolidone is advantageous as an oral medication composition (1) which can be produced without requiring new manufacturing equipment; (2) which can be produced with simple steps; (3) which maintains stable solubility even with changes in the pH of the gastrointestinal tract and of which gastrointestinal tract absorption is improved.
1. An oral solid composition comprising 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or a salt thereof; polyvinylpyrrolidone; and a basic material of which the 5 w/v % aqueous solution has the pH of 10 or more.
2. The oral solid composition according to claim 1 , wherein the basic material of which the 5 w/v % aqueous solution has the pH of 10 or more is L-arginine or potassium carbonate.
3. The oral solid composition according to claim 1 , wherein the basic material of which the 5 w/v % aqueous solution has the pH of 10 or more is L-arginine.
4. The oral solid composition according to any one of claim 1 to claim 4 , wherein the oral solid composition contains a water-soluble excipient.
5. The oral solid composition according to claim 1 , wherein the oral solid composition is a tablet or a capsule.
6. The oral solid composition according to claim 1 , wherein the oral solid composition is a tablet.
7. An oral aqueous solution comprising 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or a salt thereof and polyvinylpyrrolidone.
8. The oral aqueous solution according to claim 7 , wherein the concentration of 3- {5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid is 0.01-20 w/v %.
9. The oral aqueous solution according to claim 7 or claim 8 , wherein the amount of polyvinylpyrrolidone is 1-10 times per that of 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid.
10. The oral aqueous solution according to claim 7 , wherein the pH of the oral aqueous solution is 3 to 9.
11. The oral solid composition according to claim 2 , wherein the oral solid composition is a tablet or a capsule.
12. The oral solid composition according to claim 3 , wherein the oral solid composition is a tablet or a capsule.
13. The oral solid composition according to claim 2 , wherein the oral solid composition is a tablet.
14. The oral solid composition according to claim 3 , wherein the oral solid composition is a tablet.
15. The oral aqueous solution according to claim 8 , wherein the pH of the oral aqueous solution is 3 to 9.
16. The oral aqueous solution according to claim 9 , wherein the pH of the oral aqueous solution is 3 to 9.